拉米夫定对乙肝合并肺结核患者肝功能及HBV DNA含量的影响

Effects of Lamivudine on hepatic function and HBV DNA contents in patients with hepatitis B in combination with pulmonary tuberculosis

目的探讨拉米夫定对乙肝合并肺结核患者肝功能及HBV DNA含量的影响。方法将70例慢性乙型肝炎合并肺结核患者随机分为对照组和治疗组,每组35例,对照组采取护肝+抗结核治疗,治疗组在基础上加用拉米夫定,观察疗程3个月,比较两组治疗前后血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBIL)水平及HBV DNA含量。结果治疗3个月后,治疗组血清ALT、AST、TBIL水平及HBV DNA含量明显低于对照组,差异均有统计学意义(P<0.05)。结论拉米夫定可明显改善乙肝合并肺结核患者肝功能,并降低HBV DNA含量。

Objective To explore the effects of lamivudine on hepatic function and HBV DNA contents in patients with hepatitis B in combination with pulmonary tuberculosis. Methods Seventy patients with hepatitis B in combination with pulmonary tuberculosis were randomly divided into control group and therapeutic group. Each group included 35 cases. Control group received treatment of protection liver and anti-tuberculosis. In addition to these treatments,therapeutic group was given lamivudine. The course of treatment was 3 months. Serum alanine transarninase （ALT） ,glutamic-oxal（o） acetic transaminase （AST） and total bilirubin （TBIL） levels and HBV DNA contents were compared between control group and therapeutic group. Results After treatments of 3 months,Serum alanine transarninase （ALT）,glutamic-oxal（o） acetic transaminase （AST） and total bilirubin （TBIL） levels and HBV DNA contents were significantly reduced in therapeutic group as compared to control group （P 0.05）. Conclusion Lamivudine is able to markedly alleviate hepatic function and decrease HBV DNA contents in patients with hepatitis B in combination with pulmonary tuberculosis.